Re: "Planned" Retirement - Srdjan (Serge) Stankovic
Serge is "retiring", this is great news! Under his watch, the company failed to grow the pipeline and position the company's lead drug to succeed. Instead, they wasted patent life and failed to meet Pima's potential. They absolutely have someone ready to step in. I'm thinking, they announce at the earnings call or shortly thereafter.
They may just have something with ACP-204 and believe Serge is not the one to lead it through development and trials. At best, he stays on behind the scenes as an advisor. I wasn't comfortable with his communication skills and always felt he should not be out front. Too many times, Davis would have to step in and clarify his statements and better present the information.